Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Biogen Inc., EBITDA calculation
US$ in thousands
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Biogen Inc. EBITDA decreased from 2019 to 2020 and from 2020 to 2021. |
Enterprise Value to EBITDA Ratio, Current
Biogen Inc., current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (US$ in thousands) | |
| Enterprise value (EV) | 42,927,124) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 2,521,400) |
| Valuation Ratio | |
| EV/EBITDA | 17.03 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| AbbVie Inc. | 22.28 |
| Amgen Inc. | 14.12 |
| Bristol-Myers Squibb Co. | 7.70 |
| Danaher Corp. | 22.32 |
| Eli Lilly & Co. | 92.41 |
| Gilead Sciences Inc. | 13.36 |
| Johnson & Johnson | 15.95 |
| Merck & Co. Inc. | 40.60 |
| Pfizer Inc. | 21.76 |
| Regeneron Pharmaceuticals Inc. | 13.88 |
| Thermo Fisher Scientific Inc. | 23.04 |
| Vertex Pharmaceuticals Inc. | 23.96 |
| EV/EBITDA, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 16.35 |
| EV/EBITDA, Industry | |
| Health Care | 16.23 |
Based on: 10-K (reporting date: 2021-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Biogen Inc., historical EV/EBITDA calculation, comparison to benchmarks
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Enterprise value (EV)1 | 35,890,898) | 44,904,281) | 60,176,147) | 67,941,735) | 75,435,189) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 2,521,400) | 5,732,500) | 7,698,600) | 6,750,700) | 6,460,600) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 14.23 | 7.83 | 7.82 | 10.06 | 11.68 | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| AbbVie Inc. | 13.44 | 21.34 | 13.68 | — | — | |
| Amgen Inc. | 13.22 | 12.24 | 12.26 | — | — | |
| Bristol-Myers Squibb Co. | 8.65 | 34.35 | 23.84 | — | — | |
| Danaher Corp. | 21.05 | 26.68 | 25.23 | — | — | |
| Eli Lilly & Co. | 29.85 | 23.67 | 21.40 | — | — | |
| Gilead Sciences Inc. | 8.57 | 24.90 | 11.77 | — | — | |
| Johnson & Johnson | 14.47 | 18.20 | 16.28 | — | — | |
| Merck & Co. Inc. | 12.18 | 16.05 | 13.66 | — | — | |
| Pfizer Inc. | 8.64 | 15.78 | 9.17 | — | — | |
| Regeneron Pharmaceuticals Inc. | 6.68 | 12.70 | 14.80 | — | — | |
| Thermo Fisher Scientific Inc. | 20.21 | 18.72 | 19.74 | — | — | |
| Vertex Pharmaceuticals Inc. | 18.92 | 14.81 | 37.82 | — | — | |
| EV/EBITDA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 13.16 | 18.90 | — | — | — | |
| EV/EBITDA, Industry | ||||||
| Health Care | 13.87 | 16.50 | — | — | — | |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
3 2021 Calculation
EV/EBITDA = EV ÷ EBITDA
= 35,890,898 ÷ 2,521,400 = 14.23
4 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Biogen Inc. EV/EBITDA ratio increased from 2019 to 2020 and from 2020 to 2021. |